ArticleCureus2026
Screen Positivity and Feasibility of Newborn Thyroid Screening Using Postnatal Venous Thyroid-Stimulating Hormone: A Retrospective Cohort Study From Northeast India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCongenital hypothyroidism (CH) is a preventable cause of intellectual disability when detected and treated early. Postnatal thyroid-stimulating hormone (TSH)-based newborn screening is recommended in India, but evidence from resource-limited settings remains scarce. This study aimed to determine the screen positivity rate and evaluate the feasibility of postnatal venous TSH-based screening.
methodsThis retrospective study included live births at a tertiary care hospital in Northeast India between March 2023 and November 2024 who underwent CH screening using venous TSH estimation at 48-72 hours of life. A TSH value of >20 mIU/L was considered screen-positive according to the Indian Society for Pediatric and Adolescent Endocrinology guidelines. Screen positivity rates were calculated, and associations with clinical variables were explored. Continuous variables were summarized using descriptive statistics, and associations were evaluated using the chi-square test or Fisher's exact test, as appropriate. A p value of <0.05 was considered statistically significant.
resultsOf 1,622 live births, 1,132 (69.8%) underwent screening, of whom 1,064 (94.0% of those screened) had analyzable results. Most exclusions resulted from early discharge before sampling and inadequate blood samples. The mean (standard deviation) TSH value was 4.49 (5.19) mIU/L. Nine newborns were screen-positive, yielding a screen positivity rate of 0.85% (8.5 per 1,000 newborns), which decreased to 0.47% after excluding clinically unwell neonates. Among screen-positive newborns, median TSH values were lower in preterm than in term newborns (25.44 vs. 37.52 mIU/L). Maternal thyroid disorder, present in 22.4% of mothers, was not significantly associated with abnormal neonatal TSH (p = 0.73).
conclusionPostnatal venous TSH-based screening was feasible but associated with moderate attrition. The observed screen positivity reinforces the importance of universal newborn screening for CH in this region. Strengthening follow-up and optimizing sample collection, including evaluation of cord blood screening, may enhance the effectiveness of newborn screening programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.